Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Clinical validation of tissue and liquid companion diagnostics for BRAF V600E detection in non-small cell lung cancers from the PHAROS study.

Cancer research communications·2026

Same author

Development and Implementation of a Machine Learning Model for Prediction of Surgical Case Duration.

Joint Commission journal on quality and patient safety·2026

Same author

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Breast Implant-Associated Malignancies: Current Recommendations for Workup and Management.

Plastic and reconstructive surgery·2026

Same author

Yoga for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: Results of a Randomized Controlled Trial.

JCO oncology practice·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Surgery: Future directions in multimodality therapy for NSCLC.

Anne S Tsao¹, Jack A Roth, Roy S Herbst

¹Department of Thoracic and Head & Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Nature Reviews. Clinical Oncology

|December 24, 2009

Summary

This summary is machine-generated.

Trimodality therapy combining lobectomy with other treatments shows clinical benefit for stage III non-small-cell lung cancer (NSCLC) patients with N2 nodal disease. This approach offers a promising option for this challenging patient population.

More Related Videos

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 17, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Area of Science:

Oncology
Thoracic Surgery
Pulmonology

Background:

Stage III non-small-cell lung cancer (NSCLC) presents a heterogeneous patient group with debated treatment strategies.
The role of surgical resection in advanced NSCLC remains a complex clinical question.

Discussion:

Albain and colleagues' trial investigated trimodality therapy, including lobectomy, for patients with pathologic N2 stage III NSCLC.
This multimodal approach demonstrated a clinical benefit, addressing the controversy surrounding surgical intervention in this cohort.

Key Insights:

Trimodality therapy with lobectomy provides significant clinical benefit for specific stage III NSCLC patients.
Pathologic nodal status (N2) is a critical factor in determining treatment efficacy for stage III NSCLC.

Outlook:

The findings suggest a potential paradigm shift in the management of stage III NSCLC.
Further research is warranted to explore the long-term implications and optimize trimodality treatment protocols for lung cancer therapy.